21093-54-9

Basic information

• Product Name: 3-Pyridinemethanol, 2-(phenylamino)-
• CAS NO: 21093-54-9
• Molecular Formula: C12H12N2O
• Molecular Weight: 200.24
• Mol File: 21093-54-9.mol
• Article Data: 13

Chemical Properties

• CAS DataBase Reference: 3-Pyridinemethanol, 2-(phenylamino)-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinemethanol, 2-(phenylamino)-(21093-54-9)
• EPA Substance Registry System: 3-Pyridinemethanol, 2-(phenylamino)-(21093-54-9)

Safety Data

• Hazardous Substances Data: 21093-54-9(Hazardous Substances Data)

Upstream product

• 16344-24-4 2-(phenylamino)nicotinic acid 
• 67-56-1 methanol 
• 121-43-7 Trimethyl borate 
• 75-09-2 dichloromethane 
• 115891-18-4 ethyl 2-(phenylamino)pyridine-3-carboxylate 
• 1452-94-4 ethyl 2-chloronicotinate 
• 62-53-3 aniline 
• 2942-59-8 2-chloronicotinic acid 

Downstream Products

• 21093-56-1 (3-Chloromethyl-pyridin-2-yl)-phenyl-amine; hydrochloride 
• 1239164-65-8 3-oxo-1-cyclohexenyl 2-oxo-1-phenyl-1,2-dihydro-1,8-naphthyridine-3-carboxylate 
• 1239164-22-7 3-(2-hydroxy-6-oxo-1-cyclohexenecarbonyl)-1-phenyl-1,8-naphthyridin-2(1H)-one 
• 1239164-95-4 2-oxo-1-phenyl-1,2-dihydro-[1,8]naphthyridine-3-carboxylic acid ethyl ester 
• 1239164-66-9 2-oxo-1-phenyl-1,2-dihydro-1,8-naphthyridine-3-carboxylic acid chloride 

Relevant articles and documents

Design, synthesis and biological evaluation of novel 4-(pyrrolo[2,3-d]pyrimidine-4-yloxy)benzamide derivatives as potential antitumor agents

Cancer is a major cause of death worldwide. Small molecule inhibitors have become a major therapeutic treatment for cancer. In this study, a series of novel 4-(pyrrolo[2,3-d]pyrimidine-4-yloxy)benzamide derivatives were designed, synthesized and evaluated

Synthesis and antiproliferative activity of pyrrolo[2,3-b]pyridine derivatives bearing the 1,8-naphthyridin-2-one moiety

A series of pyrrolo[2,3-b]pyridine derivatives bearing the 1,8-naphthyridin-2-one moiety were synthesized, and evaluated for their antiproliferative activity against four cancer cell lines (HT-29, A549, H460, and U87MG) and six tyrosine kinases (c-Met, Flt-3, PDGFR-β VEGFR-2, EGFR, and c-Kit) inhibitory activities in vitro. Most compounds showed moderate to excellent potency, with the most promising analogue 32 showing Flt-3/c-Met IC50 value of 1.16/1.92 nM. Structure-activity relationship studies indicated that the hydrogen atom served as R1 group was benefited to the potency, and mono-electron-withdrawing groups (mono-EWGs) on the phenyl ring (such as R3 = 4-F) showed a higher preference for antiproliferative activity.

Preparation and application of 2-carbamoyl-4-heteroaromatic pyridine compounds

The invention provides 2-carbamoyl-4-heteroaromatic pyridine derivatives and pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof. The substituent groups R1, R2 and Y have definitions in the specification. The invention further relates to compounds with a general formula I having strong effects of inhibiting c-Met kinase, and also relates to an application of the compounds and pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof in preparation of medicines for treating diseases caused by abnormal high expression of the c-Met kinase, particularly an application in preparation of medicines for treating and/or preventing cancers.